(Q37869883)

24 August 2017

1 reference

title

Non-alcoholic fatty liver disease: a massive problem (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

12 May 2020

main subject

fatty liver disease

0 references

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Christopher P Day

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

publication date

1 April 2011

1 reference

24 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

page(s)

176-178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

12 May 2020

cites work

1 reference

12 December 2020

Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease

1 reference

12 December 2020

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

From fat to inflammation

1 reference

12 December 2020

1 reference

12 December 2020

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

1 reference

12 December 2020

Hepatic histology in obese patients undergoing bariatric surgery

1 reference

12 December 2020

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

12 December 2020

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

12 December 2020

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

1 reference

12 December 2020

Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance

1 reference

12 December 2020

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

12 December 2020

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

1 reference

12 December 2020

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

12 December 2020

Current and future therapeutic strategies in NAFLD.

1 reference

12 December 2020

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

12 December 2020

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

12 December 2020

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

10.7861/CLINMEDICINE.11-2-176

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5922746&resulttype=core&format=json

12 May 2020

1 reference